Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina
Top Cited Papers
Abstract
No abstract availableKeywords
Funding Information
- U.S. Food and Drug Administration
- Abbott Vascular
- National Health Service Corps
- University Hospitals
- St George's University Hospitals NHS Foundation Trust
This publication has 21 references indexed in Scilit:
- Unlocking Success: Strategies for Preventing and Managing Complications in Chronic Total Occlusion Percutaneous Coronary Intervention ProceduresThe American Journal of Cardiology, 2024
- Bayesian transition models for ordinal longitudinal outcomesStatistics in Medicine, 2024
- Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trialThe Lancet, 2024
- A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable AnginaNew England Journal of Medicine, 2023
- 2021 ACC/AHA/SCAI Guideline for Coronary Artery RevascularizationJACC, 2022
- Initial Invasive or Conservative Strategy for Stable Coronary DiseaseNew England Journal of Medicine, 2020
- The IMPACTOR-CTO TrialJACC: Cardiovascular Interventions, 2018
- A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusionsEuropean Heart Journal, 2018
- Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trialThe Lancet, 2018
- Assessment of blinding in clinical trialsControlled Clinical Trials, 2004